Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7827.016 | 0.8294 | 0.7648 | 1.4950 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7827.016 | 0.8649 | 0.8149 | 1.4950 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7827.016 | 0.9226 | 0.8951 | 1.4950 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7827.016 | 0.8638 | 0.8135 | 1.4950 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.267 | uM | 7827.016 | 0.8531 | 0.7984 | 1.4950 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 1.33 | uM | 7827.016 | 0.9207 | 0.8924 | 1.4950 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 6.67 | uM | 7827.016 | 0.7344 | 0.6269 | 1.4950 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 33.3 | uM | 7827.016 | 0.5459 | 0.3340 | 1.4950 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 9347.132 | 1.0106 | 1.0144 | 1.4716 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.000427 | uM | 9347.132 | 1.0334 | 1.0452 | 1.4716 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.00213 | uM | 9347.132 | 0.9715 | 0.9611 | 1.4716 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.0107 | uM | 9347.132 | 0.8001 | 0.7187 | 1.4716 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.0533 | uM | 9347.132 | 0.9056 | 0.8696 | 1.4716 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 0.267 | uM | 9347.132 | 1.0280 | 1.0378 | 1.4716 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 1.33 | uM | 9347.132 | 0.8938 | 0.8531 | 1.4716 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 6.67 | uM | 9347.132 | 0.7965 | 0.7135 | 1.4716 | |
| HCC1569 | HER2amp | Basal A | Gefitinib | EGFR | ErbB | 33.3 | uM | 9347.132 | 0.8880 | 0.8449 | 1.4716 | |
| HCC1806 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7829.016 | 1.0037 | 1.0038 | 1.9532 | |
| HCC1806 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7829.016 | 1.0242 | 1.0246 | 1.9532 | |
| HCC1806 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7829.016 | 0.9817 | 0.9812 | 1.9532 | |
| HCC1806 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7829.016 | 1.0120 | 1.0123 | 1.9532 | |
| HCC1806 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7829.016 | 0.9757 | 0.9750 | 1.9532 | |
| HCC1806 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.267 | uM | 7829.016 | 0.8041 | 0.7888 | 1.9532 | |
| HCC1806 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 1.33 | uM | 7829.016 | 0.6601 | 0.6169 | 1.9532 | |
| HCC1806 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 6.67 | uM | 7829.016 | 0.6523 | 0.6071 | 1.9532 |